ACM Global Laboratories   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Rochester NY United States (1997)

Organization Overview

First Clinical Trial
2008
NCT00668850
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

ACM | ACM Biolabs | ACM Global Europe | ACM Global Laboratories | ACM Laboratories | ACM Pivotal Global Central Laboratory

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 3)

Conjunctivitis (Phase 2)

Diabetes Mellitus (Phase 3)

Lupus Erythematosus, Systemic (Phase 1)

Pain, Postoperative (Phase 3)

Pneumonia (Phase 2)

Pneumonia, Bacterial (Phase 2)

Tinea (Phase 3)

Tinea Pedis (Phase 3)

Toothache (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 11